NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: G
Post# of 231
(Total Views: 195)
Posted On: 10/07/2019 3:41:08 PM
NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-
,” by researchers in Australia, Spain and Austria, supports the belief that non-viral delivery could be a safer alternative for patients than viral vectors, also potentially speeding production time while reducing costs. Genprex was not involved in the study that used a different nanotechnology. “One of the biggest differentiators between Genprex and other gene therapy companies developing technologies to treat cancer and other serious diseases is our proprietary non-viral nanoparticle delivery system, which has already been used to safely treat more than 50 patients to date,” Genprex Chairman and CEO Rodney Varner said in the news release. “Most gene therapy research has been focused on using viral delivery systems to deliver genes to cancer cells, and today most approved gene therapies for non-blood cell therapies use a viral vector to deliver the gene to the patient. Our proprietary non-viral delivery system enables us to potentially treat patients with a system that may be safer, with lower production costs and better scalability.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-
,” by researchers in Australia, Spain and Austria, supports the belief that non-viral delivery could be a safer alternative for patients than viral vectors, also potentially speeding production time while reducing costs. Genprex was not involved in the study that used a different nanotechnology. “One of the biggest differentiators between Genprex and other gene therapy companies developing technologies to treat cancer and other serious diseases is our proprietary non-viral nanoparticle delivery system, which has already been used to safely treat more than 50 patients to date,” Genprex Chairman and CEO Rodney Varner said in the news release. “Most gene therapy research has been focused on using viral delivery systems to deliver genes to cancer cells, and today most approved gene therapies for non-blood cell therapies use a viral vector to deliver the gene to the patient. Our proprietary non-viral delivery system enables us to potentially treat patients with a system that may be safer, with lower production costs and better scalability.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)